Pursuant to the agreement, Cipher has granted Ranbaxy Pharmaceuticals (RPI) the exclusive right to market, sell and distribute CIP-Isotretinoin in the US, its territories and possessions. Under the
A global syndicate of current investors participated in this round including SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Bioventures, BioMedinvest and VI Partners. This funding
The joint ventures (JVs) will be majority owned by Meda and Valeant will own a minority interest. The joint ventures will pursue the regulatory filings and manage the
The new trial will evaluate the safety and efficacy of mipomersen in patients who have heterozygous familial hypercholesterolemia and coronary artery disease. It is a randomized, double-blind, placebo-controlled
This placebo controlled, double-blind, randomized two-way crossover trial (RD-02) was performed by Parexel’s clinical research unit in Europe. In this study, eight volunteers per dose group each received
In September 2006, Alnylam was awarded a federal contract providing the company with up to $23 million in funding over a four-year period to develop small interfering RNAs
In collaboration with Merck & Co, deforolimus is currently being studied in multiple clinical trials, both alone and in combination with other therapies, in patients with several different
Results from Phase I, Phase II and Phase III double-blinded clinical validation studies on prostate tissues obtained from multiple sites, including those tested in collaboration with MD Anderson
These two patents are said to cover the basic composition of viral particles resulting from Lipid Sciences’s proprietary viral delipidation process. Lewis Meyer, president and CEO of Lipid
GlaxoSmithKline (GSK) conducted this review upon learning that the analysis undertaken by the D:A:D cohort had found an unexpected but potential association between highly active antiretroviral therapy (HAART)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.